Investigational drug · Phase 3
Etentamig
Also called: ABBV-383, TNB-383B
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
8 still active
All registered trials
14
Any phase or sponsor naming "Etentamig"
First trial start
2019
Jun 24, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Etentamig", any sponsor or status.
- Phase 110
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Relapsed or Refractory Multiple Myeloma
- Amyloid Light Chain (AL) Amyloidosis
- Immunoglobulin Light Chain (AL) Amyloidosis
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "Etentamig" as an intervention, largest first.
AbbVieAbbVie (ABBV)
NCT07095452 · 680 participants (planned) · Start Jan 8, 2026 · Primary completion Mar 2041
Drug: Etentamig; Lenalidomide and 4 more · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Los Angeles, California; Denver, Colorado · 49 sites in all
AbbVieAbbVie (ABBV)
NCT06892522 · 602 participants (planned) · Start Jun 30, 2025 · Primary completion Dec 2035
Drug: Etentamig; Lenalidomide and 9 more · For: Multiple Myeloma
Sites: Duarte, California; Irvine, California; San Francisco, California · 36 sites in all
- A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple MyelomaPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT07728188 · 520 participants (planned) · Start Oct 20, 2026 · Primary completion Feb 2033
Drug: Etentamig; Pomalidomide and 4 more · For: Relapsed or Refractory Multiple Myeloma
Sites: Ogden, Utah; Jerusalem, Israel; Kyoto, Japan · 7 sites in all
- Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT06158841 · 421 participants · Start May 19, 2024 · Primary completion Dec 2027
Drug: Etentamig; Carfilzomib and 5 more · For: Multiple Myeloma
Sites: Birmingham, Alabama; Phoenix, Arizona; Berkeley, California · 166 sites in all
- Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) AmyloidosisPivotal-lookingNot yet recruiting
AbbVieAbbVie (ABBV)
NCT07793422 · 370 participants (planned) · Start Nov 29, 2026 · Primary completion Dec 2034
Drug: Etentamig; Daratumumab and 6 more · For: Amyloid Light Chain (AL) Amyloidosis
- A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)Pivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06953960 · 325 participants (planned) · Start Jul 23, 2025 · Primary completion Dec 2030
Drug: Surzetoclax; Daratumumab and 3 more · For: Multiple Myeloma
Sites: Los Angeles, California; New Haven, Connecticut; Boston, Massachusetts · 51 sites in all
AbbVieAbbVie (ABBV)
NCT05259839 · 283 participants · Start Oct 20, 2022 · Primary completion Sep 2033
Drug: Etentamig; Dexamethasone and 3 more · For: Relapsed/Refractory Multiple Myeloma
Sites: Little Rock, Arkansas; Miami, Florida; Tampa, Florida · 49 sites in all
AbbVieAbbVie (ABBV)
NCT05650632 · 250 participants (planned) · Start Mar 21, 2023 · Primary completion Aug 2029
Drug: Etentamig (ABBV-383) · For: Multiple Myeloma
Sites: Phoenix, Arizona; Springdale, Arkansas; Aurora, Colorado · 44 sites in all
- Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple MyelomaNot yet recruiting
Universitätsklinikum Hamburg-EppendorfAcademic, hospital or other
NCT07600151 · 220 participants (planned) · Start Dec 1, 2026 · Primary completion Sep 30, 2036
Drug: Etentamig; Isatuximab and 1 more · For: Myeloma Multiple; Myeloma
Sites: Hamburg, Germany
AbbVieAbbVie (ABBV)
NCT06896916 · 135 participants (planned) · Start Aug 7, 2025 · Primary completion Mar 2036
Drug: Etentamig; Iberdomide · For: Multiple Myeloma
Sites: Beverly Hills, California; Denver, Colorado; St Louis, Missouri · 27 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Etentamig in Relapsed/Refractory Multiple Myeloma: Pooled Phase 1 Data of an Investigational BCMA Bispecific Antibody.
Baljevic M, Voorhees P, Rodriguez C, et al. · Blood 2026
- Bispecific antibodies targeting B-cell maturation antigen in multiple myeloma: Current clinical applications, challenges and future directions.
Manzato E, Cocchetto G, Barbato S, et al. · Cancer 2026
- Dilution displacement enabled measurement of total ligand levels in the presence of an anti-ligand antibody using LBA.
Zhang C, Sheridan JP, Boehm N, et al. · Bioanalysis 2026
- Safety and Efficacy of Anti-B-cell Maturation Antigen (Anti-BCMA) Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma: A Systematic Review of Clinical Trials.
Khan AA, Rahman M, Jawed I, et al. · Cureus 2025
- Comprehensive Review of Bispecific Antibody Constructs In Multiple Myeloma: Affinities, Dosing Strategies and Future Perspectives.
Waldschmidt JM, Rasche L, Kortüm KM, et al. · Clin Lymphoma Myeloma Leuk 2025
- A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.
D'Souza A, Shah N, Rodriguez C, et al. · J Clin Oncol 2022
Also in development for Multiple Myeloma
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Anitocabtagene AutoleucelCART-ddBCMAPhase 34 trials
Gilead Sciences · Multiple Myeloma, Newly Diagnosed Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.